Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

For Alice Shaw, Dana-Farber Cancer Institute’s Chief of Strategic Partnerships, the best is however yet to come. “There is so much excitement around these RAS therapies,” says Shaw ...

Considering that the incidence of specific RAS mutations varies from cancer type to cancer type, it is clear the need for developing effective treatments against other RAS-mutations different to ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha ... evaluating BBO-10203 in advanced cases of breast cancer, colorectal cancer, and non-small cell lung ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

RICHMOND - A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA ...